Karmanos Cancer Institute Researchers Study Bisphosphonates And Their Affect On Early Stage Breast Cancer

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties. The findings were announced at the 2010 American Society of Clinical Oncology Annual Meeting.